Literature DB >> 15689366

Bilateral subthalamotomy in Parkinson's disease: initial and long-term response.

L Alvarez1, R Macias, G Lopez, E Alvarez, N Pavon, M C Rodriguez-Oroz, J L Juncos, C Maragoto, J Guridi, I Litvan, E S Tolosa, W Koller, J Vitek, M R DeLong, J A Obeso.   

Abstract

We conducted an open label pilot study of the effect of bilateral subthalamotomy in 18 patients with advanced Parkinson's disease. In seven patients, the first subthalamotomy pre-dated the second by 12-24 months ('staged surgery'). Subsequently, a second group of 11 patients received bilateral subthalamotomy on the same day ('simultaneous surgery'). Patients were assessed according to the CAPIT (Core Assessment Program for Intracerebral Transplantation) protocol, a battery of timed motor tests and neuropsychological tests. Evaluations were performed in the 'off' and 'on' drug states before surgery and at 1 and 6 months and every year thereafter for a minimum of 3 years after bilateral subthalamotomy. Compared with baseline, bilateral subthalamotomy induced a significant (P < 0.001) reduction in the 'off' (49.5%) and 'on' (35.5%) Unified Parkinson's Disease Rating Scale (UPDRS) motor scores at the last assessment. A blind rating of videotape motor exams in the 'off' and 'on' medication states preoperatively and at 2 years postoperatively also revealed a significant improvement. All of the cardinal features of Parkinson's disease as well as activities of daily living (ADL) scores significantly improved (P < 0.01). Levodopa-induced dyskinesias were reduced by 50% (P < 0.01), and the mean daily levodopa dose was reduced by 47% at the time of the last evaluation compared with baseline (P < 0.0001). Dyskinesias occurred intraoperatively or in the immediate postoperative hours in 13 patients, but were generally mild and short lasting. Three patients developed severe generalized chorea that gradually resolved within the next 3-6 months. Three patients experienced severe and persistent postoperative dysarthria. In two, this coincided with the patients exhibiting large bilateral lesions also suffering from severe dyskinesias. No patient exhibited permanent cognitive impairment. The motor benefit has persisted for a follow-up of 3-6 years. This study indicates that bilateral subthalamotomy may induce a significant and long-lasting improvement of advanced Parkinson's disease, but the clinical outcome was variable. This variability may depend in large part on the precise location and volume of the lesions. Further refinement of the surgical procedure is mandatory.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15689366     DOI: 10.1093/brain/awh397

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  46 in total

1.  Allosteric modulation of the group III mGlu4 receptor provides functional neuroprotection in the 6-hydroxydopamine rat model of Parkinson's disease.

Authors:  Matthew J Betts; Michael J O'Neill; Susan Duty
Journal:  Br J Pharmacol       Date:  2012-08       Impact factor: 8.739

2.  Changing views of basal ganglia circuits and circuit disorders.

Authors:  Mahlon DeLong; Thomas Wichmann
Journal:  Clin EEG Neurosci       Date:  2010-04       Impact factor: 1.843

Review 3.  Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.

Authors:  Yoland Smith; Thomas Wichmann; Stewart A Factor; Mahlon R DeLong
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

4.  Symptomatic and neuroprotective effects following activation of nigral group III metabotropic glutamate receptors in rodent models of Parkinson's disease.

Authors:  P J Austin; M J Betts; M Broadstock; M J O'Neill; S N Mitchell; S Duty
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

Review 5.  A fronto-striato-subthalamic-pallidal network for goal-directed and habitual inhibition.

Authors:  Marjan Jahanshahi; Ignacio Obeso; John C Rothwell; José A Obeso
Journal:  Nat Rev Neurosci       Date:  2015-11-04       Impact factor: 34.870

6.  Lesion of the centromedian thalamic nucleus in MPTP-treated monkeys.

Authors:  Jose L Lanciego; Maria C Rodríguez-Oroz; Francisco J Blesa; Lydia Alvarez-Erviti; Jorge Guridi; Pedro Barroso-Chinea; Yoland Smith; Jose A Obeso
Journal:  Mov Disord       Date:  2008-04-15       Impact factor: 10.338

Review 7.  The history and future of deep brain stimulation.

Authors:  Jason M Schwalb; Clement Hamani
Journal:  Neurotherapeutics       Date:  2008-01       Impact factor: 7.620

8.  Autonomous initiation and propagation of action potentials in neurons of the subthalamic nucleus.

Authors:  Jeremy F Atherton; David L Wokosin; Sankari Ramanathan; Mark D Bevan
Journal:  J Physiol       Date:  2008-10-02       Impact factor: 5.182

Review 9.  Pathophysiology of parkinsonism.

Authors:  Adriana Galvan; Thomas Wichmann
Journal:  Clin Neurophysiol       Date:  2008-05-07       Impact factor: 3.708

Review 10.  Milestones in research on the pathophysiology of Parkinson's disease.

Authors:  Thomas Wichmann; Mahlon R DeLong; Jorge Guridi; Jose A Obeso
Journal:  Mov Disord       Date:  2011-05       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.